The Jewish General Hospital, known officially as the Sir Mortimer B. Davis Jewish General Hospital since 1978, is an acute-care teaching hospital in Montreal, Quebec, Canada. The hospital is affiliated with McGill University and has 637 beds, one of the most of a hospital site in Canada.

There are 637 beds in Jewish General Hospital.

During the past decade, Jewish General Hospital conducted 303 clinical trials. In the 10-year time frame, 303 clinical trials started and 110 clinical trials were completed, i.e. on average, 36.3% percent of trials that started reached the finish line to date. In the past 5 years, 95 clinical trials started and 63 clinical trials were completed. i.e. 66.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Jewish General Hospital" #1 sponsor was "Jewish General Hospital" with 77 trials, followed by "Hoffmann-La Roche" with 27 trials sponsored, "Canadian Cancer Trials Group" with 20 trials sponsored, "Sir Mortimer B. Davis - Jewish General Hospital" with 20 trials sponsored and "NSABP Foundation Inc" with 20 trials sponsored. Other sponsors include 342 different institutions and companies that sponsored additional 172 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Jewish General Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 32 trials as a collaborator, "Canadian Institutes of Health Research (CIHR)" with 29 trials as a collaborator, "Jewish General Hospital" with 14 trials as a collaborator, "McGill University Health Centre/Research Institute of the McGill University Health Centre" with 13 trials as a collaborator and "AstraZeneca" with 11 trials as a collaborator. Other collaborators include 372 different institutions and companies that were collaborators in the rest 259 trials.

According to Clinical.Site data, the most researched conditions in "Jewish General Hospital" are "Breast Cancer" (35 trials), "Prostate Cancer" (21 trials), "Colorectal Cancer" (12 trials), "Cancer" (9 trials) and "Neoplasms" (8 trials). Many other conditions were trialed in "Jewish General Hospital" in a lesser frequency.

Most popular intervention types in "Jewish General Hospital" are "Drug" (318 trials), "Other" (103 trials), "Radiation" (39 trials), "Biological" (37 trials) and "Procedure" (34 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (43 trials), "Paclitaxel" (20 trials), "Laboratory Biomarker Analysis" (13 trials), "Pembrolizumab" (13 trials) and "Docetaxel" (12 trials). Other intervention names were less common.

The vast majority of trials in "Jewish General Hospital" are 409 trials for "All" genders, 67 trials for "Female" genders and 33 trials for "Male" genders.

Currently, there are 210 active trials in "Jewish General Hospital". 3 are not yet recruiting, 95 are recruiting, 108 are Active, not recruiting, and 4 are Enrolling by invitation. In total, there were 217 completed trials in Jewish General Hospital, 3 suspended trials, and 50 terminated clinical trials to date.

Out of the total trials that were conducted in Jewish General Hospital, 57 "Phase 1" clinical trials were conducted, 158 "Phase 2" clinical trials and 180 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 19 trials, and there were also 78 trials that are defined as “Not Applicable".

Jewish General Hospital has several departments that took part in Clinical trials: "Jewish General Hospital; Clinical Research Unit" - 5 trials, "Jewish General Hospital; Research Unit" - 4 trials, "Peter Brojge Lung Cancer Center, Jewish General Hospital" - 3 trials, "Cardiovascular Prevention Centre, Jewish General Hospital" - 2 trials